Novartis’ Cosentyx shines in ankylosing spondylitis and psoriatic arthritis
pharmafile | June 15, 2017 | News story | Research and Development |Â Â Cosentyx, NovartisÂ
Novartis has released new data on the efficacy of its drug Cosentyx (secukinumab) in the treatment of life-long inflammatory diseases ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). The data places the drug as the only fully human interleukin-17A (IL-17A) inhibitor to offer efficacy and safety up to three years
These successes were represented in the findings of two Phase 3 studies. In the MEASURE 1 study, it was found that, after three years of treatment, 80% of patients consistently recorded a response of ASAS 20 (Assessment of Spondyloarthritis International Society). This links to the previous results of the FUTURE 1 study which showed that Cosentyx displayed consistent improvements in disease signs in 80% of patients over the same period, according to ACR 20 response, a metric used by the American College of Rheumatology.
The FUTURE 2 study investigated the drug’s efficacy in PsA, finding that after just three weeks, half of patients reported at least a 20% improvement in disease-related pain, according to the Visual Analogue Scale, with Cosentyx proving 10% more effective in this regard than placebo by the fourth week.
Cosentyx is currently the only drug in its class to be authorised for the treatment of PsA, AS, and psoriasis, having been used in over 80,000 patients worldwide.
“These data reconfirm that Cosentyx provides patients with long-lasting relief from the symptoms of ankylosing spondylitis and psoriatic arthritis, as well as now demonstrating rapid pain relief from psoriatic arthritis”, explained Vas Narasimhan, Global Head of Drug Development and Chief Medical Officer at Novartis. “We are pleased that Cosentyx continues to provide sustained benefits for patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.”
Matt Fellows
Related Content
Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
